MassNextGen Showcase

Massachusetts Entrepreneurs

Nov. 2 | 12:30-4 p.m. | Takeda

2026 MassNextGen Entrepreneurs



Cellens, Jean Pham, Co-Founder & CEO
Cellens is pioneering a new modality in cancer diagnostics to bring clarity and comfort to cancer monitoring. Their AI-driven mechanobiology platform, BioFeel™, creates a new class of biomarkers to detect recurrence early, accurately, and without invasive procedures. Starting with bladder cancer, the company is building a future where cancer monitoring is simple, precise and patient-friendly.



EntoCellular, Sophia Letcher, Co-Founder & CEO
At EntoCellular, they grow insect cells as new ingredients for pet food. Nearly half of all pet food ingredients come from livestock, and they are on a mission to create nutritious, sustainable, and cruelty-free alternatives. EntoCellular is a B2B company and their ingredient is high-quality animal protein produced without farming animals.



RedPoint Oncology, Mengdie Wang, Co-Founder & CEO
RedPoint Oncology is building a new payload class for targeted cancer therapies, designed to eliminate therapy-resistant tumors where current treatments fail. Their modular payload platform pairs seamlessly with existing antibodies and linkers, unlocking the future potential of hundreds of targeting technologies that depend on better payloads. RedPoint Oncology is committed to delivering more effective treatments for patients with urgent unmet needs.

• • • •


MassNextGen Entrepreneurs



Akeyna, Karen Cronholm, CEO & Co-Founder
Akeyna is revolutionizing safety in injection procedures with its unique smart needle which detects blood vessels, reducing the risk of severe complications in critical injections. Their beachhead product will be used to prevent blindness, necrosis, and stroke from dermal fillers in the large and growing aesthetic cash-pay industry, since reimbursement is not required. Their proprietary smart needle is affordable, so small it can fasten onto any standard syringe, and can notify injectors when a vessel is detected in real-time.

Massachusetts
LIFE SCIENCES CENTER

masslifesciences.com/massnextgen | MassNextGen@masslifesciences.com



DoriNano, Claire Zeng, Co-Founder, CEO, & CTO
DoriNano, a Harvard University spinout, is pioneering a new class of programmable nanoparticle delivery systems enabled by proprietary DNA origami nanotechnology. Compared with conventional delivery modalities such as lipid nanoparticles (LNPs) and adeno-associated viruses (AAVs), DoriNano's platform offers superior precision, modularity, stability, and targetability, enabling programmable multi-cargo loading, repeat dosing potential, and scalable manufacturing across a broad range of therapeutic applications.



Gelectric Medical, Leah Borden, CEO & Co-Founder
Gelectric Medical is a seed-stage medical device company developing breakthrough electroadhesive and thermoresponsive hydrogels that allow safe, gentle, and reversible adhesion for both skin and internal tissue applications. Their technologies include NüGel, for neonatal device securement, and AnastoTape, a suture and staple free solution for gastrointestinal (internal) tissue procedures.



General Prognostics, Sean Matsuoka, Co-Founder & CEO
General Prognostics (GPx) is a digital health company developing "Bloodless Blood Tests" that use AI and longitudinal wearable data to detect clinically meaningful physiological changes before patients become symptomatic. Their lead product, CardioID, is designed to identify patterns associated with worsening heart failure and alert clinicians early enough to evaluate and intervene before deterioration leads to hospitalization.



InnoTech Precision Medicine, Roya Khosravi-Far, President & CEO
InnoTech Precision Medicine is a diagnostics company developing a saliva-based, AI-enabled point-of-care platform that integrates genotypic, phenotypic, and relevant patient information. With 98% diagnostic accuracy, Recognize™ provides AI-driven decision support for early detection of HPV-driven oropharyngeal squamous cell carcinoma, with planned expansion into cervical cancer and broader oncology.



PhagePro, Minmin Yen, CEO & Co-Founder
PhagePro is developing phage-based antibacterials for everyone, everywhere. Its lead product, ProphaLytic-Vc (PVC), is an orally administered, cold-chain-independent, three-phage prophylactic designed to prevent Vibrio cholerae infection. By leveraging naturally occurring bacteriophages to provide targeted protection without contributing to antimicrobial resistance, PhagePro aims to make bacterial infection prevention accessible and equitable across both high- and low-resource settings.

Massachusetts
LIFE SCIENCES CENTER